Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.

[1]  E. Van Cutsem,et al.  Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Ychou,et al.  473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results , 2017 .

[3]  E. Van Cutsem,et al.  Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial , 2016, British Journal of Cancer.

[4]  S. Tjulandin,et al.  Second-line treatment of metastatic gastric cancer: Current options and future directions. , 2015, World journal of gastroenterology.

[5]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[6]  P. Hegde,et al.  Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications). , 2014 .

[7]  C. Fuchs,et al.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.

[8]  D. Cunningham,et al.  Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. , 2014, The Lancet. Oncology.

[9]  E. Mochiki,et al.  C-reactive protein as a significant prognostic factor for stage IV gastric cancer patients. , 2013, Anticancer research.

[10]  M. Detmar,et al.  VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis. , 2013, Cancer research.

[11]  P. Carmeliet,et al.  Markers of response for the antiangiogenic agent bevacizumab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Chang-qing Yang,et al.  Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. , 2013, International journal of clinical and experimental pathology.

[13]  Chibo Liu,et al.  Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling. , 2012, Oncology letters.

[14]  Joon-Oh Park,et al.  Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Hinke,et al.  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). , 2011, European journal of cancer.

[16]  Z. Ye,et al.  Expression of Hepatocyte Growth Factor and Basic Fibroblast Growth Factor as Prognostic Indicators in Gastric Cancer , 2009, Anatomical record.

[17]  G. Neufeld,et al.  Pro-angiogenic cytokines and their role in tumor angiogenesis , 2006, Cancer and Metastasis Reviews.

[18]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Teti,et al.  Serum levels of interleukin 1β, interleukin 8 and tumour necrosis factor α as markers of gastric cancer , 2006 .

[20]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Stacker,et al.  Focus on lymphangiogenesis in tumor metastasis. , 2005, Cancer cell.

[22]  K. Shirouzu,et al.  VEGF significance in peritoneal recurrence from gastric cancer , 2005, Gastric Cancer.

[23]  C. Fondevila,et al.  p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer , 2004, British Journal of Cancer.

[24]  N. Yang,et al.  Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. , 2003, Cancer research.